-
-
-
-
-
-
-
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
-
-
-
-
-
-
-
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
-
-
-
-
-
-
-
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
-
-
-
-
-
-
-
Harrow to Acquire Melt Pharmaceuticals
-
-
-
-
-
-
-
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
-
-
-
-
-
-
-
Harrow Health (HROW) Announces Transitional Pass-Through Reimbursement Status for TRIESENCE 40 mg/mL
-
-
-
-
-
-
-
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
-
1,180,150 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

